Medicines/Item |
Section |
Status |
Link Name / Link URL |
Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563:Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
Abiraterone |
08.03.04.02 |
Restricted Use
|
NICE TAG 259: Abiraterone for castration resistant prostate cancer |
Abiraterone |
08.03.04.02 |
Restricted Use
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Adalimumab |
11.04.02 |
Restricted Use
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
Adefovir Dipivoxil |
05.03.03.01 |
Restricted Use
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
Adefovir Dipivoxil |
05.03.03.01 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
Adrenaline / epinephrine |
03.04.03 |
Formulary
|
NICE 134: Anaphylaxis: Assessment and referral after emergency treatment |
Afatinib |
08.01.05 |
Restricted Use
|
NICE TA310: Afatinib for non-small-cell lung cancer |
Aflibercept |
08.01.05 |
Restricted Use
|
Visual impairment due to mycopic choroidal neovascularisation: afibercept |
Aflibercept |
08.01.05 |
Restricted Use
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA486:Aflibercept for treating choroidal neovascularisation |
Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA409:Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
Alectinib |
08.01.05 |
Restricted Use
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
Alemtuzumab |
08.02.03 |
Restricted Use
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
Alirocumab |
02.12 |
Restricted Use
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Alteplase |
02.10.02 |
Restricted Use
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
Amoxicillin |
05.01.01.03 |
Formulary
|
COVID19: NICE (NG165) - managing suspected or confirmed pneumonia in the community |
Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TAG156: Anti-D in pregnant women |
Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
Apremilast |
13.05.03 |
Restricted Use
|
NICE TA 419: Apremilast for treating moderate to severe plaque psoriasis |
Apremilast |
13.05.03 |
Restricted Use
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
Aripiprazole |
04.02.01 |
Formulary
|
Bipolar disorder (children) - aripiprazole (NICE TA292) |
Aripiprazole |
04.02.01 |
Formulary
|
Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213) |
Arsenic Trioxide |
08.01.05 |
Restricted Use
|
NICE TA526: treatment for acute promyelocytic leukaemia |
Asfotase alfa |
09.08.01 |
Non Formulary
|
NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia |
Ataluren |
10.02 |
Restricted Use
|
HST3 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA584:Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
Avatrombopag |
09.01.04 |
Restricted Use
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
Avelumab |
08.02.03 |
Restricted Use
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
Avelumab |
08.02.03 |
Restricted Use
|
NICE TA517: Avelumab for treating metastaic Merkel cell carcinoma |
Axitinib |
08.01.05 |
Restricted Use
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
Axitinib |
08.01.05 |
Restricted Use
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
Azacitidine |
08.01.03 |
Restricted Use
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
Azacitidine |
08.01.03 |
Restricted Use
|
NICE TA218: azacitidine for myelodysplastic syndromes |
Azithromycin |
05.01.05 |
Restricted Use
|
NICE evidence summary: Long-term azithromycin for CF |
Azithromycin |
05.01.05 |
Restricted Use
|
NICE evidence summary: Long-term azithromycin for non-CF bronchiectasis |
Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466:Baricitinib for moderate to severe rheumatoid arthritis |
Basiliximab |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
Belimumab |
10.01 |
Restricted Use
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
Bendamustine |
08.01.01 |
Restricted Use
|
NICE TA 216: Bendamustine for CLL |
Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA263: Breast cancer with capecitabine |
Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA214: Breast Cancer with taxane |
Bevacizumab |
08.01.05 |
Restricted Use
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
Bevacizumab |
08.01.05 |
Restricted Use
|
NICE Evidence summary: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
Bivalirudin |
02.08.01 |
Formulary
|
NICE TAG 230 : Bivalirudin for the treatment of STEMI, 2011 |
Bivalirudin |
02.08.01 |
Formulary
|
NICE CG 94:Unstable angina and NSTEMI |
Blinatumomab |
08.02 |
Restricted Use
|
NICE TA450:Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
Blinatumomab |
08.02 |
Restricted Use
|
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: hepatitis |
Bortezomib |
08.01.05 |
Formulary
|
NICE TAG370: Bortezomib for previously untreated mantle cell lymphoma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TAG228: 1st line treatment of multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TAG311: Bortezomib for induction therapy in multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TAG129: Multiple myeloma - bortezomib |
Bosutinib |
08.01.05 |
Restricted Use
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
Botulinum Toxin Type A |
04.09.03 |
Restricted Use
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
Brentuximab vedotin |
08.01.05 |
Restricted Use
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
Brentuximab vedotin |
08.01.05 |
Restricted Use
|
NICE TA524: for treating CD30-positive Hodgkin lymphoma |
Brentuximab vedotin |
08.01.05 |
Restricted Use
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
Brexpiprazole |
04.02.01 |
Non Formulary
|
Bipolar disorder (children) - aripiprazole (NICE TA292) |
Brexpiprazole |
04.02.01 |
Non Formulary
|
Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213) |
Brigatinib |
08.01.05 |
Restricted Use
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
Budesonide |
01.05.02 |
Formulary
|
NICE: Evidence Summary (ESNM58) |
Burosumab |
06.06.02 |
Restricted Use
|
HST8: Burosumab for treating X-linked hypophosphataemia in children and young people |
Cabazitaxel |
08.01.05 |
Restricted Use
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
Cabozantinib |
08.01.05 |
Restricted Use
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Restricted Use
|
NICE TA463:Cabozantinib for previously treated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Restricted Use
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
Cangrelor |
02.09 |
Non Formulary
|
NICE advice [ESNM64] |
Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
Cannabidiol (CBD) |
04.08.01 |
Restricted Use
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
Cannabidiol (CBD) |
04.08.01 |
Restricted Use
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Colorectal cancer - capecitabine and tegafur uracil |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
Caplacizumab |
08.02.03 |
Restricted Use
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
Carbamazepine |
04.02 |
Non Formulary
|
NICE evidence summary: carbamazepine for behavioural disturbances in dementia |
Carfilzomib |
08.01.05 |
Restricted Use
|
NICE TA657:Carfilzomib for previously treated multiple myeloma |
Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Carmustine |
08.01.01 |
Restricted Use
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Ceftolozane & tazobactam |
05.01.02 |
Restricted Use
|
NICE 2016: Evidence summary of new medicines: UTI |
Ceftolozane & tazobactam |
05.01.02 |
Restricted Use
|
NICE 2016: Evidence summary of new medicines: intra-abdominal |
Ceritinib |
08.01.05 |
Restricted Use
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
Ceritinib |
08.01.05 |
Restricted Use
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445:Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
Cetirizine |
03.04.01 |
Formulary
|
NICE advice [ESUOM31]: Chronic urticaria: off-label doses of cetirizine |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Ciclosporin |
11.99.99.99 |
Restricted Use
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
Cinacalcet |
09.05.01.02 |
Restricted Use
|
NICE TA117: Hyperparathyroidism - cinacalcet |
Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
Clonidine |
02.05.02 |
Formulary
|
NICE Evidence Summary: Clonidine for ADHD in children and young people |
Clopidogrel |
02.09 |
Formulary
|
NICE Evidence summary: Clopidogrel for transient ischaemic attack |
Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414:Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
Codeine |
04.07.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
Colecalciferol |
09.06.04 |
Formulary
|
NICE ES28: Vitamin D, no evidence for preventing/ treating Covid-19 |
Colesevelam |
01.09.02 |
Formulary
|
NICE Evidence Summary: Colesevelam for bile acid malabsorption |
Colistimethate for nebulisation |
05.01.07 |
Formulary
|
NICE ESUOM25: Non-cystic fibrosis bronchiectasis: colistimethate sodium |
Colistimethate inhaler |
05.01.07 |
Restricted Use
|
NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) |
Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459:Collagenase clostridium histolyticum for Dupuytren’s contracture |
Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Restricted Use
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
Dabrafenib |
08.01.05 |
Restricted Use
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
Dabrafenib |
08.01.05 |
Restricted Use
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
Dabrafenib |
08.01.05 |
Restricted Use
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Daclatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating T1D |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating T2D |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating T2D |
Daratumumab |
08.01.05 |
Restricted Use
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
Daratumumab |
08.01.05 |
Restricted Use
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
Darbepoetin Alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Darbepoetin Alfa |
09.01.03 |
Restricted Use
|
NICE NG8: Anaemia in chronic kidney disease |
Darolutamide |
08.03.04.02 |
Restricted Use
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
Dasabuvir |
05.03.03.02 |
Restricted Use
|
NICE TAG365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Debrisoft |
A5.07 |
Restricted Use
|
NICE MTG17: Debrisoft for acute and chronic wounds |
Decitabine |
08.01.03 |
Non Formulary
|
NICE: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) |
Degarelix |
08.03.04.02 |
Restricted Use
|
NICE TA404:Degarelix for treating advanced hormone-dependent prostate cancer |
Denosumab |
06.06.02 |
Restricted Use
|
NICE: Bone metastases from solid tumours - denosumab: guidance (TA265 ) |
Denosumab |
06.06.02 |
Restricted Use
|
NICE TA204: Osteoporotic fractures - denosumab |
Dexamethasone |
06.03.02 |
Formulary
|
COVID 19 steroid prescribing briefing (NICE) |
Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA349: Diabetic Macular Oedema |
Diltiazem 2% Cream/Ointment |
01.07.04 |
Restricted Use
|
NICE evidence summary |
Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
Dimethyl Fumarate |
13.05.02 |
Restricted Use
|
NICE TA475: Dimethyl fumarate for plaque psoriasis |
DIMETHYL SULPHOXIDE Bladder Instillation 50% |
07.04.04 |
Restricted Use
|
NICE Unlicensed Medicine Summary 26: Dimethyl Sulfoxide Bladder Instillation |
Dinutuximab beta |
08.02.04 |
Restricted Use
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Domperidone |
04.06 |
Formulary
|
NICE: Enteral feeds in children and young people: domperidone |
Doxorubicin |
08.01.02 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
Doxycycline |
05.01.03 |
Formulary
|
COVID19: NICE (NG165) - managing suspected or confirmed pneumonia in the community |
Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
Dulaglutide |
06.01.02.03 |
Formulary
|
NICE: Evidence Summary (ESNM59) |
Dupilumab |
13.05.03 |
Restricted Use
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
Durvalumab |
08.01 |
Restricted Use
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer |
Eculizumab |
09.01.03 |
Restricted Use
|
NICE HST1: Eculizumab for atypical haemolytic uraemic syndrome |
Eculizumab |
09.01.03 |
Restricted Use
|
NICE evidence summary: eculizumab for prevention of C3 glomerulopathy post-transplant |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular AF |
Eliglustat |
09.08.01 |
Non Formulary
|
NICE HST5- Eliglustat for treating type 1 Gaucher disease |
Elosulfase alfa |
09.08.01 |
Non Formulary
|
NICE HST2: Elosulfase alfa for treating mucopolysaccharidosis type IVa |
Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TAG 293: Eltrombopag for treating chronic ITP |
Eluxadoline |
01.04.02 |
Non Formulary
|
NICE TA471 |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating T2D |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
Entecavir |
05.03.03.01 |
Restricted Use
|
NICE CG165: Hepatitis B (incorporates TA153) |
Entecavir |
05.03.03.01 |
Restricted Use
|
NICE TA153: Hepatitis B (chronic) - entecavir |
Entrectinib |
08.01.05 |
Formulary
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
Entrectinib |
08.01.05 |
Formulary
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA316: Enzalutamide for prostate cancer |
EpiFix® |
A5.04 |
Non Formulary
|
NICE EpiFix for Chronic Wounds |
Eplerenone |
02.02.03 |
Restricted Use
|
NICE NG106: Chronic heart failure |
Epoetin alfa |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Epoetin alfa |
09.01.03 |
Restricted Use
|
NICE NG8: Anaemia in chronic kidney disease |
Epoetin beta |
09.01.03 |
Restricted Use
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
Epoetin beta |
09.01.03 |
Restricted Use
|
NICE NG8: Anaemia in chronic kidney disease |
Eribulin |
08.01.05 |
Restricted Use
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
Eribulin |
08.01.05 |
Restricted Use
|
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating T2D |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a DPP4i for treating T2D |
Erythromycin |
05.01.05 |
Formulary
|
NICE Evidence summary: Erythromycin for gastroparesis in adults |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA35: Adult psoriasis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
Etanercept |
13.05.03 |
Formulary
|
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA35: Adult psoriasis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA35: Adult psoriasis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
Etelcalcetide |
09.05.01.02 |
Restricted Use
|
NICE TA448: Etelcalcetide for secondary hyperparathyroidism |
Everolimus |
08.02.02 |
Non Formulary
|
NICE TA348: Preventing Rejection in Liver Transplant |
Everolimus |
08.01.05 |
Restricted Use
|
NICE TA348: Preventing Rejection in Liver Transplant |
Everolimus |
08.01.05 |
Restricted Use
|
NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment |
Everolimus |
08.01.05 |
Restricted Use
|
NICE TA421:Everolimus with exemestane in advanced breast cancer after endocrine therapy |
Everolimus |
08.01.05 |
Restricted Use
|
NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Evolocumab |
02.12 |
Restricted Use
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Exenatide prolonged release |
06.01.02.03 |
Formulary
|
NICE TAG 248- MR exenatide |
Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
Febuxostat |
10.01.04 |
Restricted Use
|
NICE TA164: Hyperuricaemia - febuxostat |
Fentanyl |
04.07.02 |
Restricted Use
|
Moderate to severe acute post-operative pain: fentanyl transdermal patch |
Filgrastim |
09.01.06 |
Formulary
|
NICE KTT15: Biosimilar medicines |
Finasteride |
06.04.02 |
Restricted Use
|
NICE CG97 Lower urinary tract symptoms in men |
Fingolimod |
08.02.04 |
Restricted Use
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
Fludrocortisone |
06.03.01 |
Formulary
|
Postural hypotension in adults: fludrocortisone |
FLUNARIZINE 5mg capsules |
20 |
Formulary
|
NICE Unlicensed Evidence summary: Flunarizine for migraine prophylaxis |
Fluocinolone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
Fluocinolone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
Fluoxetine |
04.03.03 |
Formulary
|
NICE evidence summary: Fluoxetine for hypersexuality |
Fluticasone furoate & vilanterol |
03.02 |
Formulary
|
NICE New Medicine Evidence Summary 34: Fluticasone furoate & vilanterol inhaler |
Fluticasone furoate, umeclidinium & vilanterol inhaler |
03.02 |
Formulary
|
COPD: fluticasone furoate, umeclidinium and vilanterol (Trelegy) |
Follitropin Alfa biosimilar |
06.05.01 |
Restricted Use
|
NICE KTT15: Biosimilar medicines |
Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide |
03.02 |
Formulary
|
NICE Evidence Summary (ES17) June 2018 |
Fosfomycin |
05.01.07 |
Formulary
|
NICE Evidence summary: Fosfomycin for resistant urinary tract infections |
Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
Gabapentin |
04.07.03 |
Formulary
|
CKS - Restless legs syndrome |
Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
Gefitinib |
08.01.05 |
Restricted Use
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA85: Pancreatic cancer - gemcitabine |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Gemtuzumab ozogamicin |
08.01.05 |
Restricted Use
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
Gilteritinib |
08.01.05 |
Restricted Use
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
Glatiramer Acetate |
08.02.04 |
Formulary
|
Glatiramer for the treatment of MS |
Glecaprevir/Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
GLIADEL wafer Carmustine 7.6mg |
20 |
Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
GLYCERYL TRINITRATE Ointment 0.2% |
20 |
Non Formulary
|
NICE Evidence summary: 0.2% glyceryl trinitrate ointment for chronic anal fissures |
Glycopyrrolate/ indacaterol inhaler |
03.01.04 |
Non Formulary
|
NICE New Medicine Evidence Summary 33: indacaterol/glycopyrronium (Ultibro Breezhaler) |
Glycopyrronium |
01.02 |
Formulary
|
NICE evidence summary: Glycopyrronium for hypersalivation |
Glycopyrronium tablets |
20 |
Non Formulary
|
NICE Evidence Summary: glycopyrronium for hyperhidrosis |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: psoriatic arthritis |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Golimumab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Golimumab |
10.01.03 |
Non Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
Guanfacine |
04.04 |
Formulary
|
NICE ESNM70: Attention deficit hyperactivity disorder in children and young people |
Guselkumab |
13.05.03 |
Restricted Use
|
NICE TA521: Treatment in moderate to severe plaque psoriasis |
Haloperidol |
04.02.01 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
Hydrocortisone sodium succinate |
06.03.02 |
Formulary
|
COVID 19 steroid prescribing briefing (NICE) |
Hyoscine Butylbromide |
01.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
Idelalisib |
08.01.05 |
Restricted Use
|
NICE TA604: Idelalisib for treating refractory follicular lymphoma (not recommended) |
Idelalisib |
08.01.05 |
Restricted Use
|
NICA TA359: Chronic lymphocytic leukaemia - Idelalisib |
Imatinib |
08.01.05 |
Restricted Use
|
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Imatinib |
08.01.05 |
Restricted Use
|
NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Infliximab |
01.05.03 |
Restricted Use
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis |
Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Infliximab |
01.05.03 |
Restricted Use
|
NICE KTT15: Biosimilar medicines |
Infliximab |
01.05.03 |
Restricted Use
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Inotuzumab Ozogamicin |
08.01.05 |
Restricted Use
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
Insulin Glargine biosimilar |
06.01.01.02 |
Formulary
|
NICE KTT15: Biosimilar medicines |
Interferon Alfa-2b |
08.02.04 |
Non Formulary
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
Interferon Beta-1a |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
Interferon Beta-1a |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
Interferon beta-1b |
08.02.04 |
Restricted Use
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
Iodozyme® |
A5.03.02 |
Non Formulary
|
NICE Medtech innovation briefing on Oxyzyme and Iodozyme |
Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Ipilimumab |
08.01.05 |
Restricted Use
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
Isatuximab |
08.01.05 |
Restricted Use
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
Ivabradine |
02.06.03 |
Restricted Use
|
NICE Guidance on Stable Angina (2011) |
Ivermectin |
13.10.04 |
Restricted Use
|
NICE Evidence summary: Ivermectin for difficult-to-treat scabies |
Ivermectin cream |
13.06 |
Formulary
|
NICE new medicine summary: Inflammatory lesions of papulopustular rosacea |
Ixazomib |
08.01.05 |
Restricted Use
|
NICE: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505) |
Ixekizumab |
13.05.02 |
Restricted Use
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Ketamine oral solution |
04.07.03 |
Formulary
|
NICE Unlicensed medicine review 27: Ketamine for chronic pain |
Lamivudine |
05.03.01 |
Restricted Use
|
CG165: Chronic Hepatitis B |
Lanadelumab |
03.04.03 |
Restricted Use
|
NICE TA605: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
Lapatinib |
08.01.05 |
Restricted Use
|
NICE TA257: Lapatinib in HER-2 positive metastatic breast cancer |
Larotrectinib |
08.01.05 |
Restricted Use
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
Ledipasvir and Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TAG363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
Lefamulin |
05.01.07 |
Non Formulary
|
NICE evidence summary: Rifaximin for pouchitis |
Lenalidomide |
08.02.04 |
Restricted Use
|
NICE: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505) |
Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
Lesinurad |
10.01.04 |
Non Formulary
|
NICE: Lesinurad for treating chronic hyperuricaemia in people with gout (TA506) |
Lesinurad & Allopurinol |
10.01.04 |
Non Formulary
|
NICE: Lesinurad for treating chronic hyperuricaemia in people with gout (TA506) |
Levomepromazine |
04.06 |
Restricted Use
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
Liposomal Cytarabine-Daunorubicin |
08.01.02 |
Restricted Use
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
Lorazepam |
04.01.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
Lorlatinib |
08.01.05 |
Restricted Use
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
Lumacaftor + Ivacaftor |
03.07 |
Restricted Use
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
Lusutrombopag |
09.01.04 |
Restricted Use
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
Magnesium Glycerophosphate |
09.05.01.03 |
Formulary
|
NICE: Evidence Summary: Magnesium glycerophosphate |
Mannitol inhalation |
03.07 |
Restricted Use
|
NICE: Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
Melatonin |
04.01.01 |
Non Formulary
|
NICE KTT6: Hypnotics |
Melatonin |
04.01.01 |
Restricted Use
|
NICE Evidence summary: Melatonin for sleep disorders in children with ADHD |
Melatonin |
04.01.01 |
Restricted Use
|
NICE guideline [NG11]:Challenging behaviour and learning disabilities |
Mepilex Border |
A5.02.03 |
Non Formulary
|
NICE: Mepilex Border Heel & Sacrum for preventing pressure ulcers |
Mepolizumab |
03.04.02 |
Formulary
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
Metformin |
06.01.02.02 |
Formulary
|
NICE Evidence summary: Metformin for PCOS in women who are not planning pregnancy |
Midazolam |
15.01.04.01 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
Midodrine |
02.07.02 |
Formulary
|
NICE: Orthostatic hypotension: midodrine (ESNM61) |
Midostaurin |
08.01.05 |
Restricted Use
|
NICE TA523 - untreated acute myeloid leukaemia |
Mifamurtide |
08.02.04 |
Restricted Use
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
Mifepristone |
07.01.02 |
Formulary
|
NICE Evidence summary: Mifepristone for induction of labour in late intrauterine fetal death |
Migalastat |
09.08.01 |
Non Formulary
|
NICE HST4: Migalastat for treating Fabry disease |
Minocycline |
05.01.03 |
Non Formulary
|
NICE therapeutic topic: Minocycline |
Mirabegron |
07.04.02 |
Formulary
|
NICE: TA290 - Mirabegron for overactive bladder |
Modafinil |
04.04 |
Restricted Use
|
NICE Evidence Summary: Modafinil for fatigue in multiple sclerosis |
Modafinil |
04.04 |
Restricted Use
|
NICE Evidence Summary: Modafinil for excessive daytime sleepiness in Parkinson’s disease |
Morphine |
04.07.02 |
Formulary
|
COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community |
Mycophenolate Mofetil |
08.02.01 |
Restricted Use
|
NICE Evidence summary: Mycophenolate for scleroderma |
Mycophenolate Mofetil |
08.02.01 |
Restricted Use
|
NICE Evidence summary: Mycophenolate for SLE |
Mycophenolic acid (sodium) |
08.02.01 |
Formulary
|
NICE Evidence summary: Mycophenolate for scleroderma |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
Naldemedine |
01.06.06 |
Formulary
|
NICE TA651: Naldemedine for opioid induced constipation |
Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
Neratinib |
08.03.04.01 |
Restricted Use
|
NICE TA 612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
Netupitant and Palonosetron |
04.06 |
Restricted Use
|
NICE ESNM69: Prevention of chemotherapy induced nausea and vomiting in adults |
Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for first line treatment of CML |
Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high dose imatinib for CML |
Nintedanib |
03.11 |
Restricted Use
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
Nintedanib |
03.11 |
Restricted Use
|
NICE TA347: Recurrent non-small-cell lung cancer |
Niraparib |
08.02.04 |
Restricted Use
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA655: for advanced squamous non-small-cell lung cancer after chemotherapy |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA462:Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
Nivolumab |
08.02.04 |
Restricted Use
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (not recommended) |
Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
Obinutuzumab |
08.02.03 |
Restricted Use
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
Ocrelizumab |
08.02.03 |
Restricted Use
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
Ocrelizumab |
08.02.03 |
Restricted Use
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
Olaparib |
08.02.04 |
Restricted Use
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
Olaparib |
08.02.04 |
Restricted Use
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278: Omalizumab for treating allergic asthma |
Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Restricted Use
|
NICE TAG365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Omega-3-Acid Ethyl Esters |
02.12 |
Non Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
Omega-3-Marine Triglycerides |
02.12 |
Non Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
Ondansetron |
04.06 |
Formulary
|
Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary |
Orlistat |
04.05.01 |
Formulary
|
NICE CG189: Obesity: identification, assessment and management |
Osimertinib |
08.01.05 |
Restricted Use
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
Osimertinib |
08.01.05 |
Restricted Use
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Oxyzyme® |
A5.03.02 |
Non Formulary
|
NICE Medtech innovation briefing on Oxyzyme and Iodozyme |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Restricted Use
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
Padeliporfin dipotassium |
08.03.04.02 |
Non Formulary
|
NICE TA546: Padeliporfin not recommended for untreated localised prostate cancer |
Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Panitumumab |
08.01.05 |
Restricted Use
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
Patiromer calcium |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
Pazopanib |
08.01.05 |
Restricted Use
|
NICE TA 215: Pazopanib in renal cell cancer |
Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE guidance on pegaptanib in AMD (August 2008) |
Pegaspargase |
08.01 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA 96: Hepatitis B - peginterferon alfa |
Peginterferon Alfa-2a |
08.02.04 |
Non Formulary
|
NICE TA 300: Hepatitis C - peginterferon alfa |
Pegloticase |
20 |
Non Formulary
|
NICE: TA291 - Pegloticase not recommended for severe chronic gout |
Pegylated-liposomal doxorubicin |
08.01.02 |
Restricted Use
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Restricted Use
|
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA402:Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
Pemetrexed |
08.01.03 |
Restricted Use
|
NICE TA135: Mesothelioma - pemetrexed disodium |
PENTOSAN POLYSULPHATE |
07.04.03 |
Formulary
|
Pentosan NICE TA 610 |
Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
Perampanel |
04.08.01 |
Formulary
|
NICE evidence summary |
Peristeen transanal irrigation system |
16.01 |
Non Formulary
|
NICE Peristeen transanal irrigation system |
Pertuzumab |
08.01.05 |
Restricted Use
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
Pertuzumab |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Pirfenidone |
03.11 |
Restricted Use
|
NICE: Idiopathic pulmonary fibrosis - pirfenidone (TA504) |
Pixantrone |
08.01.02 |
Restricted Use
|
TA306:Pixantrone monotherapy |
Polatuzumab Vedotin |
08.01.05 |
Restricted Use
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
Pomalidomide |
08.02.04 |
Restricted Use
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
Ponatinib |
08.01.05 |
Restricted Use
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
Pramipexole |
04.09.01 |
Formulary
|
NICE CKS: Restless legs syndrome guidance |
Prasugrel |
02.09 |
Restricted Use
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
Pregabalin |
04.07.03 |
Formulary
|
CKS - Restless legs syndrome |
Promethazine hydrochloride |
03.04.01 |
Formulary
|
NICE Evidence summary: Promethazine for rapid tranquillisation in mental health settings |
Prontosan® Wound Irrigation Solution |
A5.03.04 |
Restricted Use
|
NICE: Prontosan for Acute and Chronic wounds |
Prucalopride |
01.06.07 |
Restricted Use
|
TA211 - Constipation (women) - prucalopride |
Quetiapine |
04.02.01 |
Formulary
|
NICE Evidence summary: Quetiapine for generalised anxiety disorder |
Radium-223 dichloride |
08.03.04.02 |
Restricted Use
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE quick reference guide on osteoporosis |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161) |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160) |
Ramipril |
02.05.05.01 |
Formulary
|
NICE evidence summary: ramipril for peripheral arterial disease |
Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403:Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
Ranolazine |
02.06.03 |
Restricted Use
|
NICE Guidance on Stable Angina (2011) |
ReCell Spray on Skin system |
A5.04 |
Non Formulary
|
NICE MTG21: ReCell Spray‑On Skin system for burn injury |
Regorafenib |
08.01.05 |
Restricted Use
|
NICE TA488:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
Regorafenib |
08.01.05 |
Restricted Use
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
Remdesivir |
05.03 |
Restricted Use
|
NICE Evidence Summary 27: remdesivir for Covid-19 |
Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
Ribociclib |
08.03.04.01 |
Restricted Use
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Ribociclib |
08.03.04.01 |
Restricted Use
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Rifaximin |
05.01.07 |
Formulary
|
NICE evidence summary: Rifaximin for pouchitis |
Riluzole |
04.09.03 |
Restricted Use
|
NICE TA20: Motor neurone disease - riluzole |
Rituximab |
08.02.03 |
Restricted Use
|
NICE guidelines for rituximab |
Rituximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Rituximab |
08.02.03 |
Restricted Use
|
Rituximab for ITP-NICE evidence summary |
Rituximab |
08.02.03 |
Restricted Use
|
NICE guidelines for rituximab |
Rituximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Romiplostim |
09.01.04 |
Restricted Use
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
Ropinirole |
04.09.01 |
Formulary
|
NICE CKS: Restless legs syndrome guidance |
Rucaparib |
08.02.04 |
Restricted Use
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
Ruxolitinib |
08.01.05 |
Restricted Use
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure |
Sarilumab |
10.01.03 |
Restricted Use
|
NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis |
Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA350: Plaque Psoriasis |
Sildenafil |
02.05.01 |
Formulary
|
NICE Evidence summary: Sildenafil for digital ulcers |
Sildenafil |
02.05.01 |
Formulary
|
NICE ESUOM51: Pulmonary hypertension in neonates |
Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
Siponimod |
08.02.04 |
Restricted Use
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
Sodium Valproate |
04.02 |
Non Formulary
|
NICE evidence summary: valproate for behavioural disturbances in dementia |
Sodium Valproate |
04.08.01 |
Formulary
|
NICE 2019: Valproate: Summary of NICE guidance and safety advice |
Sodium valproate |
04.02.03 |
Formulary
|
NICE 2019: Valproate: Summary of NICE guidance and safety advice |
Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
Sofosbuvir and Velpatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
Sofosbuvir, Velpatasvir and Voxilaprevir |
05.03.03.02 |
Restricted Use
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
Somatropin |
06.05.01 |
Restricted Use
|
NICE KTT15: Biosimilar medicines |
Somatropin |
06.05.01 |
Restricted Use
|
NICE TA64: Growth hormone deficiency (adults) |
Somatropin |
06.05.01 |
Restricted Use
|
NICE TA188: Somatropin for growth failure in children |
Sorafenib |
08.01.05 |
Restricted Use
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
Sorafenib |
08.01.05 |
Restricted Use
|
NICE TA535: Sorafenib for treating differentiated thyroid cancer after radioactive iodine. |
Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
Sunitinib |
08.01.05 |
Restricted Use
|
NICE TA169: Renal cell carcinoma - sunitinib |
Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Tadalafil |
07.04.05 |
Formulary
|
NICE: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273) |
Talimogene laherparepvac |
08.02.04 |
Restricted Use
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
Teriflunomide |
08.02.04 |
Restricted Use
|
NICE TA 303: Teriflunomide for relapsing remitting MS |
Teriparatide |
06.06.01 |
Restricted Use
|
NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161) |
Teriparatide |
06.06.01 |
Restricted Use
|
NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161) |
Thiamine |
09.06.02 |
Formulary
|
NICE: Management of alcohol-related physical complications |
Thiamine |
09.06.02 |
Formulary
|
NICE: Alcohol dependence - diagnosis, assessment and management |
Thiamine |
09.06.02 |
Formulary
|
NICE: Alcohol dependence - diagnosis, assessment and management |
Thiamine |
09.06.02 |
Formulary
|
NICE: Management of alcohol-related physical complications |
Ticagrelor |
02.09 |
Restricted Use
|
NICE TAG 236: Ticagrelor for ACS |
Ticagrelor |
02.09 |
Restricted Use
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
Tildrakizumab |
13.05.03 |
Restricted Use
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
Tisagenlecleucel |
08.02.04 |
Formulary
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
Tisagenlecleucel |
08.02.04 |
Formulary
|
NICE TA554:Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
Tivozanib |
08.01 |
Restricted Use
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
Tobramycin inhaler |
05.01.04 |
Restricted Use
|
NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247:Tocilizumab in RA |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
Tofacitinib citrate |
10.01.03 |
Restricted Use
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
Tofacitinib citrate |
10.01.03 |
Restricted Use
|
NICE TA543:Tofacitinib for treating active psoriatic arthritis |
Tofacitinib citrate |
10.01.03 |
Restricted Use
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
Tolvaptan |
06.05.02 |
Restricted Use
|
NICA TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
Tolvaptan |
06.05.02 |
Non Formulary
|
NICA TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Trabectedin |
08.01.05 |
Restricted Use
|
NICE TA185: Soft tissue sarcoma - trabectedin |
Trabectedin |
08.01.05 |
Restricted Use
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Trametinib |
08.01.05 |
Restricted Use
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Trametinib |
08.01.05 |
Restricted Use
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
Tranexamic Acid |
02.11 |
Formulary
|
NICE Evidence summary: Tranexamic acid for significant haemorrhage following trauma |
Tranexamic Acid |
02.11 |
Formulary
|
NICE guideline on heavy menstrual bleeding |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA34: Breast cancer - trastuzumab |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA34: Breast cancer - trastuzumab |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Trastuzumab |
08.01.05 |
Restricted Use
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA632:Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
NICE TA458:Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
Treosulfan |
08.01.01 |
Restricted Use
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
Ulipristal |
06.07.02 |
Non Formulary
|
NICE guidelines on heavy menstrual bleeding |
UroLift system |
20 |
Non Formulary
|
NICE MTG26: UroLift for treating symptoms of BPH |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA456:Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
Valproate semisodium |
04.02.03 |
Formulary
|
NICE 2019: Valproate: summary of NICE guidance and safety advice |
Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA352: Vedolizumab for Crohn’s disease |
Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA342: Vedolizumab for ulcerative colitis |
Vemurafenib |
08.01.05 |
Restricted Use
|
NICE TA269: Vemurafenib for treating malignant melanoma |
Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
Venetoclax |
08.01.05 |
Restricted Use
|
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
Verteporfin |
11.08.02 |
Restricted Use
|
NICE Guidance 82: Age-related macular degeneration |
Vinflunine |
08.01.04 |
Restricted Use
|
NICE: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272) |
Vismodegib |
08.01.05 |
Restricted Use
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
Vortioxetine |
04.03.03 |
Formulary
|
NICE TA 367 - Vortioxetine for treating major depressive episodes |
Zoledronic Acid |
06.06.02 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
Zolpidem |
04.01.01 |
Formulary
|
NICE TAG 77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
Zopiclone |
04.01.01 |
Formulary
|
NICE TAG 77: Zaleplon, zolpidem and zopiclone for the management of insomnia |